Johnson & Johnson JNJ
NYSE JNJ
$269.99 -0.22 (-0.08%)
At close: Sep 18, 2026 · 4:00 PM EDT

Johnson & Johnson (JNJ) Non-Current Deferred Tax Liability (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Non-Current Deferred Tax Liability came in at $6.6 billion in Q2 2026, up 73.94% year-over-year from $3.8 billion in Q2 2025, and down 5.75% quarter-over-quarter from $7.0 billion in Q1 2026.

Analysis

Johnson & Johnson (JNJ) Non-Current Deferred Tax Liability (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Non-Current Deferred Tax Liability across 18 years of filings, most recently posting $6.6 billion for Q2 2026.

  • In Q2 2026, Non-Current Deferred Tax Liability rose 73.94% year-over-year to $6.6 billion; the TTM figure through Jun 2026 stood at $6.6 billion (up 73.94% YoY), while the FY2025 annual figure was $6.8 billion, up 177.41% from the prior year.
  • Non-Current Deferred Tax Liability came in at $6.6 billion for Q2 2026 at Johnson & Johnson, down from $7.0 billion in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $7.5 billion in Q1 2022 to a low of $2.4 billion in Q1 2025.
  • Average Non-Current Deferred Tax Liability over 5 years is $4.5 billion, with a median of $4.0 billion recorded in 2023.
  • Year-over-year, Non-Current Deferred Tax Liability tumbled 46.97% in 2023 and jumped 188.76% in 2026.
  • Over 5 years, Non-Current Deferred Tax Liability stood at $4.9 billion in 2022, then tumbled by 35.44% to $3.2 billion in 2023, then retreated by 23.33% to $2.4 billion in 2024, then surged by 177.41% to $6.8 billion in 2025, then slipped by 2.69% to $6.6 billion in 2026.
  • Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $6.6 billion in Q2 2026, $7.0 billion in Q1 2026, and $6.8 billion in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 650.65 Bn 629.89 Bn 17.26 Bn
2 AbbVie 466.34 Bn 459.82 Bn 12.70 Bn
3 Merck 362.11 Bn 355.02 Bn 12.21 Bn
4 Novartis Ag 267.81 Bn 260.52 Bn 11.24 Bn
5 Pfizer 157.31 Bn 145.91 Bn 10.94 Bn
6 Bristol Myers Squibb 128.75 Bn 117.69 Bn 9.25 Bn
7 Sanofi 51.80 Bn 44.84 Bn 10.79 Bn
8 Revolution Medicines 40.91 Bn 40.91 Bn -
9 BeOne Medicines 39.65 Bn 34.55 Bn 1.53 Bn
10 Incyte 25.18 Bn 20.65 Bn 1.57 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 28, 2026 6.61 Bn
Mar 29, 2026 7.01 Bn
Dec 28, 2025 6.79 Bn
Sep 28, 2025 5.99 Bn
Jun 29, 2025 3.80 Bn
Mar 30, 2025 2.43 Bn
Dec 29, 2024 2.45 Bn
Sep 29, 2024 2.95 Bn
Jun 30, 2024 2.64 Bn
Mar 31, 2024 3.17 Bn
Dec 31, 2023 3.19 Bn
Oct 1, 2023 2.62 Bn
Jul 2, 2023 3.63 Bn
Apr 2, 2023 4.42 Bn
Jan 1, 2023 3.99 Bn
Oct 2, 2022 4.95 Bn
Jul 3, 2022 5.02 Bn
Apr 3, 2022 6.42 Bn
Jan 2, 2022 7.49 Bn
Oct 3, 2021 7.15 Bn